TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10635128

Group type: EXPERIMENTAL
Intervention: Mineral enriched mouthrinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice
Number of subjects: 0
Study: 8129455

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - transdermal oestradiol (50 micrograms daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HRT 'compliers' (58.4% of HRT group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HRT 'poor-compliers' (41.6% of HRT group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 200
Study: 2569851

Group type: EXPERIMENTAL
Intervention: 30 mL syrup of ipecac
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 g activated charcoal-sorbitol solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 10
Study: 28927890

Group type: EXPERIMENTAL
Intervention: Tofacitinib (10 mg two times a day)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Etanercept (50 mg biweekly)
Number of subjects: 266
Study: 27979371

Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 26645467

Group type: EXPERIMENTAL
Intervention: Diet-Plus-Statin Therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Diet Therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diet-Plus-Statin Therapy and Diet Therapy
Number of subjects: 28
Study: 23070986

Group type: EXPERIMENTAL
Intervention: Propranolol (0.035 mg/kg body weight i.v.)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 39
Study: 21943218

Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 37

Group type: COMPARATOR
Intervention: 0.45% saline
Number of subjects: 37
Study: 18779885

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment twice daily with occlusive dressings
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment with occlusive dressings (hydrocolloid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30
Study: 16999008

Group type: EXPERIMENTAL
Intervention: Stabilized 0.454% stannous fluoride/sodium hexametaphosphate dentifrice
Number of subjects: 77

Group type: COMPARATOR
Intervention: Sodium fluoride control dentifrice
Number of subjects: 77
Study: 11830308

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (G1)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (G0)
Number of subjects: 104
Study: 10738581

Group type: EXPERIMENTAL
Intervention: AAV‐CFTR gene transfer
Number of subjects: 0
Study: 7718250

Group type: EXPERIMENTAL
Intervention: Mammography screening invitation
Number of subjects: 282777

Group type: COMPARATOR
Intervention: Official health statistics
Number of subjects: 282777
Study: 1709958

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 53

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 53
Study: 7047788

Group type: EXPERIMENTAL
Intervention: 30% idoxuridine in dimethyl sulfoxide
Number of subjects: 135

Group type: COMPARATOR
Intervention: Dimethyl sulfoxide
Number of subjects: 135

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 135
Study: 31982030

Group type: EXPERIMENTAL
Intervention: Facility-based HIV self-testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard provider-initiated training
Number of subjects: 0
Study: 31091931

Group type: EXPERIMENTAL
Intervention: Transversal temperature difference with sliding boundary condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transversal temperature difference with randomized boundary condition
Number of subjects: 0
Study: 28192831

Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Harmoknee
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (traditional warm-up)
Number of subjects: 41
Study: 25040487

Group type: EXPERIMENTAL
Intervention: Fear of Recurrence Scale (FoRSe)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Early Signs Scale (Standard)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Fear of Recurrence
Number of subjects: 169
Study: 23328350

Group type: EXPERIMENTAL
Intervention: Functional connectivity of lateral prefrontal cortex (lPFC) in adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Functional connectivity of lateral prefrontal cortex (lPFC) in children
Number of subjects: 0
Study: 21772226

Group type: EXPERIMENTAL
Intervention: Glucose (1.0 g/kg body weight) in 250 mL of water without TVV
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Glucose (1.0 g/kg body weight) in 250 mL of water with TVV
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sucralose (control) in 250 mL of water with or without TVV
Number of subjects: 25
Study: 19521532

Group type: EXPERIMENTAL
Intervention: Human and bovine PZQ treatment
Number of subjects: 4

Group type: COMPARATOR
Intervention: Human PZQ treatment only
Number of subjects: 4
Study: 17143493

Group type: EXPERIMENTAL
Intervention: UFT (5-8 mg/kg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: UFT plus CPA (1 mg/kg/one day interval)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no-treatment)
Number of subjects: 32
Study: 15551193

Group type: EXPERIMENTAL
Intervention: Zotepine (average dose of 131 +/- 49 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 80
Study: 14526301

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 75 microg every 4 hours as needed
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 105
Study: 9658724

Group type: EXPERIMENTAL
Intervention: FISH studies
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Conventional cytogenetics
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FISH and conventional cytogenetics
Number of subjects: 21
Study: 7640146

Group type: EXPERIMENTAL
Intervention: Dothiepin 75‐150 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2501094

Group type: EXPERIMENTAL
Intervention: GTN patch (7.5 mg GTN)
Number of subjects: 16
Study: 4179167

Group type: EXPERIMENTAL
Intervention: ABO compatible Rh-positive pregnancy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: ABO incompatible pregnancies
Number of subjects: 2
Study: 31495762

Group type: EXPERIMENTAL
Intervention: senofilcon A lenses
Number of subjects: 43

Group type: COMPARATOR
Intervention: lotrafilcon B lenses
Number of subjects: 43
Study: 30565198

Group type: EXPERIMENTAL
Intervention: Acoustic neurofeedback (auditory stimuli provided when concentration fell below a threshold)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no auditory stimuli provided)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acoustic neurofeedback
Number of subjects: 33
Study: 28487140

Group type: EXPERIMENTAL
Intervention: GLASS program (peer-led physical activity and object control skill intervention)
Number of subjects: 224
Study: 25163397

Group type: EXPERIMENTAL
Intervention: Everolimus plus zoledronic acid (4 mg intravenously 4-weekly)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Everolimus (10 mg daily)
Number of subjects: 30
Study: 24113263

Group type: EXPERIMENTAL
Intervention: Calorie-only condition
Number of subjects: 635

Group type: COMPARATOR
Intervention: No nutritional information
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Calorie amounts in 'traffic lights'
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Calorie, fat, sodium, and sugar shown in 'traffic lights'
Number of subjects: 635
Study: 21816918

Group type: EXPERIMENTAL
Intervention: EN stent-assisted coiling
Number of subjects: 39
Study: 19118302

Group type: COMPARATOR
Intervention: Selective Oropharyngeal Decontamination (SOD)
Number of subjects: 5939

Group type: COMPARATOR
Intervention: Selective Digestive Tract Decontamination (SDD)
Number of subjects: 5939

Group type: EXPERIMENTAL
Intervention: Standard Care
Number of subjects: 5939
Study: 19260188

Group type: EXPERIMENTAL
Intervention: Assistive devices and community-based services
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Intervention indicated by occupational therapist
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Information and instruction on mobility-related issues
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Information and instruction on personal care-related issues
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Application procedure for assistive devices and community-based services
Number of subjects: 147
Study: 15322962

Group type: EXPERIMENTAL
Intervention: Behaviour therapy (including continued psychoeducation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Medical management with methylphenidate plus psychoeducation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined treatment (behaviour therapy + medical management)
Number of subjects: 75
Study: 10778024

Group type: EXPERIMENTAL
Intervention: Mailed feedback intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9060881

Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride, 8.4 g/day orally for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride, 8.4 g/day orally after 2 weeks of treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normocholesterolemic control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemic patients
Number of subjects: 0
Study: 8101512

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 3069250

Group type: EXPERIMENTAL
Intervention: Antibiotic regimen 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic regimen 2
Number of subjects: 0
Study: 31253188

Group type: EXPERIMENTAL
Intervention: e-learning
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: blended learning
Number of subjects: 3

Group type: COMPARATOR
Intervention: waiting control group
Number of subjects: 3
Study: 28292497

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Number of subjects: 209

Group type: COMPARATOR
Intervention: Conventional glucose monitoring
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Both monitoring methods
Number of subjects: 209
Study: 25527749

Group type: EXPERIMENTAL
Intervention: Low-phenolic olive oil (20 mL daily for 6 weeks)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-phenolic olive oil (20 mL daily for 6 weeks)
Number of subjects: 69
Study: 23772999

Group type: EXPERIMENTAL
Intervention: Oral ivermectin 200 μg/kg body weight
Number of subjects: 148

Group type: COMPARATOR
Intervention: Lindane lotion 1% (two applications with a 1-week interval)
Number of subjects: 148
Study: 21944667

Group type: EXPERIMENTAL
Intervention: BTP levels
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Cystatin C levels
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Serum creatinine levels
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: mGFR
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: All markers (including eGFR)
Number of subjects: 865
Study: 18706751

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 20100317

Group type: EXPERIMENTAL
Intervention: EFICAR exercise program (3 month supervised progressive exercise program with aerobic and strength components, followed by 9 months linked with community resources)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: EFICAR exercise program
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (optimized treatment according to European Society of Cardiology guidelines)
Number of subjects: 600
Study: 16269588

Group type: EXPERIMENTAL
Intervention: FTI of 8fr/cb projections (IP)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FTI of 8fr/cb reconstructed slices (IS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Raw 8fr/cb acquisition (R8)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Raw 16fr/cb acquisition (R16)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FTI (IP)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FTI (IS)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cine display fluidity (IP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cine display fluidity (R16)
Number of subjects: 34
Study: 11943442

Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recruitment strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recruitment cost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staff time devoted to recruitment
Number of subjects: 0
Study: 9601621

Group type: EXPERIMENTAL
Intervention: L‐NGmethylarginine hydrochloride (546C88) 6 mg/kg i.v. over 15 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (5% dextrose) i.v. over 15 min
Number of subjects: 18
Study: 7978178

Group type: EXPERIMENTAL
Intervention: Glucose-xylitol 35% (1:1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucose 40%
Number of subjects: 24
Study: 2645013

Group type: EXPERIMENTAL
Intervention: Pre-operative antibiotics (group P): 3 intravenous doses of 500 mg metronidazole plus 1 g cephazolin.
Number of subjects: 700

Group type: COMPARATOR
Intervention: Intra-operative antibiotics (group T): 3 intravenous doses of 500 mg metronidazole plus 1 g cephazolin.
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI >= 26).
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Thin patients (BMI < 24).
Number of subjects: 700
Study: 1217975

Group type: EXPERIMENTAL
Intervention: Biperiden (Akineton) after slow intravenous application
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31683172

Group type: EXPERIMENTAL
Intervention: Specialty ward unit
Number of subjects: 118

Group type: COMPARATOR
Intervention: ICU
Number of subjects: 118
Study: 29544158

Group type: EXPERIMENTAL
Intervention: 12-week ACE Overcomers program (faith-based or secular)
Number of subjects: 92
Study: 27442309

Group type: EXPERIMENTAL
Intervention: PHR-delivered ACP framework
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care practices
Number of subjects: 50
Study: 24595631

Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing (IS) therapy
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Insulin-providing (IP) therapy
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1479
Study: 22038315

Group type: EXPERIMENTAL
Intervention: Warm-water bath (WWB) with tap water at 41°C for 10 minutes
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Warm-water bath (WWB) with ISCO(2) (bath additive with inorganic salts and carbon dioxide) at 41°C for 10 minutes
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Warm-water bath (WWB) with ISCO(2) at 41°C for 10 minutes
Number of subjects: 7
Study: 19388619

Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 23
Study: 17093912

Group type: EXPERIMENTAL
Intervention: 8 Gy in one fraction
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 20 Gy in five fractions
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall (both interventions)
Number of subjects: 44
Study: 15631531

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg plus statin
Number of subjects: 1861

Group type: COMPARATOR
Intervention: Statin monotherapy (lovastatin or pravastatin 10, 20 or 40 mg, simvastatin or atorvastatin 10, 20, 40 or 80 mg)
Number of subjects: 1861
Study: 11476015

Group type: EXPERIMENTAL
Intervention: Crest Extra Whitening dentifrice
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Marketed tartar control baking soda peroxide whitening dentifrice
Number of subjects: 672

Group type: COMPARATOR
Intervention: Regular dentifrice control
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Crest Extra Whitening dentifrice and Marketed tartar control baking soda peroxide whitening dentifrice
Number of subjects: 672
Study: 9734786

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 8037485

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day) for 2 years
Number of subjects: 112

Group type: COMPARATOR
Intervention: No tamoxifen administration
Number of subjects: 112
Study: 2564753

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.8 +/- 0.2 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.6-1.0 mg iv)
Number of subjects: 30
Study: 31476924

Group type: EXPERIMENTAL
Intervention: Sulpiride 50 mg/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30568596

Group type: EXPERIMENTAL
Intervention: WB-EMS training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional strength training
Number of subjects: 18
Study: 26406217

Group type: EXPERIMENTAL
Intervention: Hip abductor strengthening group (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional group (n = 15)
Number of subjects: 30
Study: 25672386

Group type: COMPARATOR
Intervention: No treatment, first bonding (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sandblasting with aluminum oxide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sandblasting + silane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Silica coating + silane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Silicatization performed in a laboratory (Rocatec system)
Number of subjects: 75
Study: 22980542

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 2 (BMP‐2) delivered by a hyaluronan‐based hydrogel at a concentration of 250 μg ml(‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Autologous bone from the iliac crest
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 2 (BMP‐2) delivered by a hyaluronan‐based hydrogel at a concentration of 50 μg ml(‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 2 (BMP‐2) delivered by a hyaluronan‐based hydrogel
Number of subjects: 7
Study: 20492060

Group type: EXPERIMENTAL
Intervention: Continued nursing intervention guided by chronotherapeutics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihypertensive medicine (control group)
Number of subjects: 0
Study: 18384419

Group type: COMPARATOR
Intervention: Acetylcholine (ACh)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcitonin gene-related peptide (CGRP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Local heating (44 degrees C)
Number of subjects: 18
Study: 16630937

Group type: EXPERIMENTAL
Intervention: Grass allergen tablet 75,000 SQ-T
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Grass allergen tablet 75,000 SQ-T (subgroup analysis)
Number of subjects: 855

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 855
Study: 12109918

Group type: EXPERIMENTAL
Intervention: RTU dobutamine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Admix dobutamine
Number of subjects: 58
Study: 10073871

Group type: EXPERIMENTAL
Intervention: Right ventricular pacing
Number of subjects: 0
Study: 8520804

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Digoxin (0.2 mg) with Pantoprazole (40 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2322635

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam SR tablet while fasting
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam SR tablet immediately after a standardized breakfast
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1 mg alprazolam conventional tablet while fasting
Number of subjects: 21
Study: 377897

Group type: EXPERIMENTAL
Intervention: PGE2-gel (0.25 mg PGE2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel (without PGE2)
Number of subjects: 20
Study: 31915046

Group type: EXPERIMENTAL
Intervention: Preoperative Danhong Injection
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Postoperative Danhong Injection
Number of subjects: 336

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 336
Study: 29789611

Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at beta frequencies during a visual temporal bisection task
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) at alpha frequencies during a visual temporal bisection task
Number of subjects: 20
Study: 27659566

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10942

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10942
Study: 26013142

Group type: EXPERIMENTAL
Intervention: Manually performed manipulations
Number of subjects: 54

Group type: COMPARATOR
Intervention: Electromechanical manipulations
Number of subjects: 54
Study: 23039340

Group type: EXPERIMENTAL
Intervention: High-polyphenol chocolate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control chocolate
Number of subjects: 10
Study: 20520602

Group type: EXPERIMENTAL
Intervention: Tesofensine
Number of subjects: 52

Group type: COMPARATOR
Intervention: D‐amphetamine (30 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 18391324

Group type: EXPERIMENTAL
Intervention: Head Mounted Display (HMD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Head Mounted Display (non-HMD)
Number of subjects: 100